Herbalife vs Nu Skin Enterprises
HLF and NUS side by side, both in wholesale trade-non-durable goods. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HLF and NUS compare
Herbalife is the larger company, worth 8.9 times as much as Nu Skin Enterprises ($1.6B against $184M).
Herbalife grew revenue faster over the last twelve months (5.5% versus −15.3% for Nu Skin Enterprises).
Herbalife keeps more of each dollar of sales as profit, with a net margin of 3.2% compared with −17.7% at Nu Skin Enterprises.
Nu Skin Enterprises pays a dividend yielding 6.3%; Herbalife does not pay one.
Nu Skin Enterprises scores higher on the StockData Score (12 against 9 for Herbalife), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HLF | NUS |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $184M |
| Share price | $15.57 | $3.78 |
| Change, 1 year | 68.7% | −60.7% |
| Change, 5 years | −59.9% | −91.5% |
| Beta (5Y) | 0.90 | 1.08 |
| Employees | 8,500 | 2,800 |
| StockData Score | ||
| Total score | 9 | 12 (better) |
| Valuation score | 4 (better) | 3 |
| Growth score | 2 | 2 |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 10.0× | – |
| P/S | 0.3× | 0.1× (better) |
| P/B | – | 0.3× |
| EV/EBITDA | 5.4× (better) | 9.4× |
| P/FCF | 5.1× | – |
| FCF yield | 19.8% (better) | −14.3% |
| Fair value | $26.93 | $12.36 |
| Margin of safety | 42.2% | 69.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 5.5% (better) | −15.3% |
| Revenue growth, 5Y average | −1.9% (better) | −10.5% |
| Net income growth (TTM) | −49.5% (better) | −314% |
| EPS growth (TTM) | −51.1% (better) | −322% |
| EPS growth, 5Y average | −4.5% | −2.6% (better) |
| Profitability | ||
| Gross margin | 77.7% (better) | 67.8% |
| Operating margin | 9.5% (better) | −2.0% |
| Net margin | 3.2% (better) | −17.7% |
| FCF margin | 6.2% (better) | −2.0% |
| Return on equity | – | −34.8% |
| Return on invested capital | 32.6% (better) | −3.1% |
| Financial health | ||
| Debt / equity | – | 0.37 |
| Net debt / EBITDA | 2.68 | 1.58 (better) |
| Interest coverage | 2.6× (better) | −1.8× |
| Current ratio | 1.20 | 2.04 (better) |
| Altman Z-score | 2.50 | 3.67 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 6.3% |
| Buyback yield | 0.70% | 8.2% (better) |
| Shareholder yield | 0.70% | 14.5% (better) |
| Ownership | ||
| Held by institutions | 100% | 74.4% |
| Held by insiders | 3.2% | 5.4% |
| Insider net buying, 12 months | −$2.5M | −$99.5K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 7.4% | 9.7% |
Go deeper
- HLF stock overview
- HLF income statement
- HLF valuation and score
- NUS stock overview
- NUS income statement
- NUS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.